{
    "2020-10-27": [
        [
            {
                "time": "",
                "original_text": "医药生物行业周报：医药行业整体回调 关注超跌板块",
                "features": {
                    "keywords": [
                        "医药",
                        "生物",
                        "行业周报",
                        "整体回调",
                        "超跌板块"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】药明康德(02359-HK)涨4.13%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "异动股",
                        "涨4.13%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2016",
                "original_text": "药明巨诺是由药明康德和美国朱诺（Juno）在2016年合资成立，药明巨诺是「药明系三号」现于10月22日-28日招股。",
                "features": {
                    "keywords": [
                        "药明巨诺",
                        "合资",
                        "药明康德",
                        "Juno",
                        "招股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2017",
                "original_text": "过去药明生物是药明康德的子公司，但在2017年药明康德一拆为三，药明生物就是其中之一。药明生物的业务模式跟药明康德是非常类似的，都建立了药物研发的全产业链。但药明康德专注于做化学药，而药明生物只做生物药，两者毫无竞争关系。",
                "features": {
                    "keywords": [
                        "药明生物",
                        "药明康德",
                        "拆分",
                        "化学药",
                        "生物药"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药CDMO子行业跟踪报告：十页带你读懂中国小分子创新药CDMO",
                "features": {
                    "keywords": [
                        "医药",
                        "CDMO",
                        "子行业",
                        "创新药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "生物医药行业深度报告：疫情、医保、集采 影响终端销售的三个关键词",
                "features": {
                    "keywords": [
                        "生物医药",
                        "疫情",
                        "医保",
                        "集采",
                        "终端销售"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-10-27",
                "original_text": "港股盘前必读：蚂蚁集团H股发行价为80港元/股 发售时间为10月27日至30日",
                "features": {
                    "keywords": [
                        "蚂蚁集团",
                        "H股",
                        "发行价",
                        "80港元",
                        "发售时间"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}